Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:23 am
Author: Getaka|Social: XLinkedIn

Nath Bio-Genes (India) Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹105.22Overvalued by 23.20%vs CMP ₹137.00

P/E (5.3) × ROE (6.8%) × BV (₹362.00) × DY (1.45%)

₹378.51Undervalued by 176.28%vs CMP ₹137.00
MoS: +63.8% (Strong)Confidence: 58/100 (Moderate)Models: 7 Under, 1 Fair, 1 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹242.5023%Under (+77%)
Graham NumberEarnings₹482.6517%Under (+252.3%)
Earnings PowerEarnings₹98.2411%Over (-28.3%)
DCFCash Flow₹620.8811%Under (+353.2%)
Net Asset ValueAssets₹360.617%Under (+163.2%)
EV/EBITDAEnterprise₹224.669%Under (+64%)
Earnings YieldEarnings₹286.007%Under (+108.8%)
ROCE CapitalReturns₹962.409%Under (+602.5%)
Revenue MultipleRevenue₹139.106%Fair (+1.5%)
Consensus (9 models)₹378.51100%Undervalued
Key Drivers: EPS CAGR 130.5% lifts DCF — verify sustainability. | Wide model spread (₹98–₹962) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 130.5%

*Investments are subject to market risks

Investment Snapshot

53
Nath Bio-Genes (India) Ltd scores 53/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health52/100 · Moderate
ROCE 7.4% WeakROE 6.8% AverageD/E 0.31 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money50/100 · Moderate
FII holding up 0.10% (6mo) Slight increaseDII holding down 3.93% MF sellingPromoter holding at 45.6% Stable
Earnings Quality40/100 · Moderate
OPM stable around 20% SteadyWorking capital: 316 days Capital intensive
Quarterly Momentum80/100 · Strong
Revenue (4Q): +22% YoY AcceleratingProfit (4Q): +27% YoY StrongOPM: 13.4% (down 7.0% YoY) Margin pressure
Industry Rank40/100 · Moderate
P/E 5.3 vs industry 15.2 Cheaper than peersROCE 7.4% vs industry 17.0% Below peersROE 6.8% vs industry 15.9% Below peers3Y sales CAGR: 5% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Nath Bio-Genes (India) Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
80/100
High
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 5.3 vs Ind 15.2 | ROCE 7.4% | ROE 6.8% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.31x | IntCov 0.0x | Current 1.22x | Borrow/Reserve 0.21x
Cash Flow Reliability
43/100
Mixed
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹42 Cr | CFO/NP N/A
Ownership Accumulation
-50
Distribution
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII -0.01 pp | DII -0.75 pp | Prom 0.00 pp
Business Momentum
+100
Watch closely
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +65.9% | Q NP +72.1% | Q OPM -4.7 pp
Derived FieldValueHow it is derived
Valuation Gap %+176.3%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.21xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change-0.01 ppLatest FII% minus previous FII%
DII Change-0.75 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-572Latest shareholder count minus previous count
Quarterly Sales Change+65.9%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+72.1%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-4.7 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:23 am

Market Cap 261 Cr.
Current Price 137
Intrinsic Value₹378.51
High / Low 239/126
Stock P/E5.29
Book Value 362
Dividend Yield1.45 %
ROCE7.35 %
ROE6.77 %
Face Value 10.0
PEG Ratio0.04

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Nath Bio-Genes (India) Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Nath Bio-Genes (India) Ltd 261 Cr. 137 239/1265.29 3621.45 %7.35 %6.77 % 10.0
Genesis IBRC India Ltd 448 Cr. 99.0 185/18.3 6.420.00 %51.6 %51.6 % 10.0
Shreeoswal Seeds & Chemicals Ltd 95.0 Cr. 10.4 20.3/9.6716.8 5.230.00 %9.88 %8.41 % 2.00
Continental Seeds and Chemicals Ltd 18.2 Cr. 13.0 32.0/13.023.6 22.50.00 %4.24 %2.87 % 10.0
Genomic Valley Biotech Ltd 8.17 Cr. 26.8 64.0/20.1 12.80.00 %11.8 %9.69 % 10.0
Industry Average354.50 Cr57.2415.2381.790.29%16.97%15.87%8.40

All Competitor Stocks of Nath Bio-Genes (India) Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 25.3044.92235.2822.5731.7443.04243.8832.1936.8749.37280.1739.7765.96
Expenses 19.6840.84198.2617.4825.9638.57206.8225.6329.3646.20241.2732.5857.12
Operating Profit 5.624.0837.025.095.784.4737.066.567.513.1738.907.198.84
OPM % 22.21%9.08%15.73%22.55%18.21%10.39%15.20%20.38%20.37%6.42%13.88%18.08%13.40%
Other Income 0.060.260.120.062.541.390.140.070.484.583.831.934.42
Interest 2.961.532.762.442.841.062.242.943.371.102.893.304.18
Depreciation 0.670.990.760.760.760.980.830.830.831.320.980.980.98
Profit before tax 2.051.8233.621.954.723.8234.132.863.795.3338.864.848.10
Tax % 34.15%12.64%0.65%17.95%16.31%16.23%0.73%-1.05%30.08%11.82%1.70%13.22%10.74%
Net Profit 1.351.5933.401.613.963.2133.892.892.664.7138.214.207.23
EPS in Rs 0.710.8417.580.852.081.6917.831.521.402.4820.112.213.80

Last Updated: February 4, 2026, 9:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 4:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 136143127142171206246271230234248265435
Expenses 102109103113131163191204193185197212377
Operating Profit 34352529404355673749505358
OPM % 25%24%19%20%24%21%22%25%16%21%20%20%13%
Other Income 11101222-8714415
Interest 4561010579111091011
Depreciation 5443111333344
Profit before tax 2626151730394957-6336424457
Tax % 5%4%6%3%2%1%-4%2%6%3%5%4%
Net Profit 2425141629385056-6735404254
EPS in Rs 15.1815.878.8510.1715.4820.2226.5629.29-35.4318.5121.1422.1728.60
Dividend Payout % 0%0%0%0%0%0%0%7%-6%11%9%9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)4.17%-44.00%14.29%81.25%31.03%31.58%12.00%-219.64%152.24%14.29%5.00%
Change in YoY Net Profit Growth (%)0.00%-48.17%58.29%66.96%-50.22%0.54%-19.58%-231.64%371.88%-137.95%-9.29%

Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:6%
5 Years:2%
3 Years:5%
TTM:17%
Compounded Profit Growth
10 Years:5%
5 Years:-3%
3 Years:21%
TTM:17%
Stock Price CAGR
10 Years:9%
5 Years:-10%
3 Years:-1%
1 Year:-22%
Return on Equity
10 Years:7%
5 Years:7%
3 Years:6%
Last Year:7%

Last Updated: September 5, 2025, 11:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:42 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 16161616191919191919191919
Reserves 6691105287450489539594523554592630668
Borrowings 2322597433587010193105108111142
Other Liabilities 85978778698010275105114158257176
Total Liabilities 1902262674555716467307907407938771,0171,005
Fixed Assets 171330207211232246247245244249250249
CWIP 0000000000000
Investments 5555555555666
Other Assets 168208231243355409479538490544622761750
Total Assets 1902262674555716467307907407938771,0171,005

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 156-143-47-239117387527
Cash from Investing Activity + -16-2-17-4-4-20-14-10-20-3-27-4
Cash from Financing Activity + 1-43059020616-22-2-10-11
Net Cash Flow -0-1-0539-2317-25343812
Free Cash Flow 125-21-1-52-45-6-1016364819
CFO/OP 49%20%-55%12%-116%-47%20%2%53%80%149%52%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow11.0013.00-34.00-45.007.00-15.00-15.00-34.00-56.00-56.00-58.00-58.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 95114130133175191159147136152139122
Inventory Days 3,8404,7434,388
Days Payable 1,3091,406586
Cash Conversion Cycle 951141302,6653,5121911591471363,954139122
Working Capital Days 126190259273447442416450427416343316
ROCE %33%26%14%10%9%8%9%10%5%7%7%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%45.59%
FIIs 0.13%0.07%0.22%0.32%0.27%0.21%0.18%0.19%0.21%0.41%0.32%0.31%
DIIs 4.62%4.62%4.37%4.37%4.37%4.37%4.37%4.37%3.94%2.25%0.76%0.01%
Public 49.65%49.71%49.81%49.72%49.76%49.80%49.83%49.83%50.24%51.73%53.31%54.08%
No. of Shareholders 33,96033,50234,36534,26335,13235,83435,42335,05634,91134,20734,12233,550

Shareholding Pattern Chart

No. of Shareholders

Nath Bio-Genes (India) Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Value Fund 126,341 0.03 2.08N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 13
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 19.8519.5218.43-35.557.34
Diluted EPS (Rs.) 19.8519.5218.43-35.557.34
Cash EPS (Rs.) 22.3222.5620.01-33.8410.16
Book Value[Excl.RevalReserv]/Share (Rs.) 339.08320.94301.60285.1635.91
Book Value[Incl.RevalReserv]/Share (Rs.) 339.08320.94301.60285.1635.91
Revenue From Operations / Share (Rs.) 192.02175.03158.58146.4786.04
PBDIT / Share (Rs.) 28.6026.5725.9420.5412.80
PBIT / Share (Rs.) 26.5924.8524.3618.929.98
PBT / Share (Rs.) 21.3621.8719.03-33.387.68
Net Profit / Share (Rs.) 20.3120.8518.42-35.467.34
NP After MI And SOA / Share (Rs.) 20.3120.8518.42-35.467.34
PBDIT Margin (%) 14.8915.1716.3514.0214.87
PBIT Margin (%) 13.8414.1915.3512.9111.59
PBT Margin (%) 11.1212.4912.00-22.788.92
Net Profit Margin (%) 10.5711.9111.61-24.208.52
NP After MI And SOA Margin (%) 10.5711.9111.61-24.208.52
Return on Networth / Equity (%) 5.996.496.10-12.4320.43
Return on Capital Employeed (%) 7.647.648.036.5926.54
Return On Assets (%) 3.764.504.41-9.117.42
Long Term Debt / Equity (X) 0.020.010.000.000.02
Total Debt / Equity (X) 0.190.180.180.170.31
Asset Turnover Ratio (%) 0.380.390.390.001.05
Current Ratio (X) 1.892.182.412.411.22
Quick Ratio (X) 0.961.301.451.270.43
Inventory Turnover Ratio (X) 1.280.000.000.000.00
Dividend Payout Ratio (NP) (%) 9.849.5910.85-5.640.00
Dividend Payout Ratio (CP) (%) 8.968.869.99-5.910.00
Earning Retention Ratio (%) 90.1690.4189.15105.640.00
Cash Earning Retention Ratio (%) 91.0491.1490.01105.910.00
Interest Coverage Ratio (X) 5.185.544.873.685.58
Interest Coverage Ratio (Post Tax) (X) 4.634.974.463.024.20
Enterprise Value (Cr.) 310.77363.13336.48494.220.00
EV / Net Operating Revenue (X) 0.851.091.121.780.00
EV / EBITDA (X) 5.727.196.8312.660.00
MarketCap / Net Operating Revenue (X) 0.750.990.891.460.00
Retention Ratios (%) 90.1590.4089.14105.640.00
Price / BV (X) 0.430.540.460.740.00
Price / Net Operating Revenue (X) 0.750.990.891.460.00
EarningsYield 0.130.110.13-0.160.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Nath Bio-Genes (India) Ltd. is a Public Limited Listed company incorporated on 14/07/1993 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L01110MH1993PLC072842 and registration number is 072842. Currently Company is involved in the business activities of Growing of non-perennial crops. Company's Total Operating Revenue is Rs. 362.31 Cr. and Equity Capital is Rs. 19.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Seeds/Tissue Culture/Bio TechnologyNath House, Aurangabad Maharashtra 431005Contact not found
Management
NamePosition Held
Mr. Satish KagliwalManaging Director
Mr. Madhukar DeshpandeDirector
Ms. Ashu JainDirector
Mrs. Jeevanlata KagliwalDirector
Mr. Vadla NagabhushanamDirector
Mr. Hitesh PurohitDirector
Mr. Akash KagliwalDirector

FAQ

What is the intrinsic value of Nath Bio-Genes (India) Ltd and is it undervalued?

As of 05 April 2026, Nath Bio-Genes (India) Ltd's intrinsic value is ₹378.51, which is 176.28% higher than the current market price of ₹137.00, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (6.77 %), book value (₹362), dividend yield (1.45 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd is trading at ₹137.00 as of 05 April 2026, with a FY2026-2027 high of ₹239 and low of ₹126. The stock is currently near its 52-week low. Market cap stands at ₹261 Cr..

How does Nath Bio-Genes (India) Ltd's P/E ratio compare to its industry?

Nath Bio-Genes (India) Ltd has a P/E ratio of 5.29, which is below the industry average of 15.23. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Nath Bio-Genes (India) Ltd financially healthy?

Key indicators for Nath Bio-Genes (India) Ltd: ROCE of 7.35 % is on the lower side compared to the industry average of 16.97%; ROE of 6.77 % is below ideal levels (industry average: 15.87%). Dividend yield is 1.45 %.

Is Nath Bio-Genes (India) Ltd profitable and how is the profit trend?

Nath Bio-Genes (India) Ltd reported a net profit of ₹42 Cr in Mar 2025 on revenue of ₹265 Cr. Compared to ₹-67 Cr in Mar 2022, the net profit shows an improving trend.

Does Nath Bio-Genes (India) Ltd pay dividends?

Nath Bio-Genes (India) Ltd has a dividend yield of 1.45 % at the current price of ₹137.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nath Bio-Genes (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports